Cytokinetics, Inc.
Cytokinetics Launches MYQORZO for Obstructive HCM Across U.S., China, and Europe
Summary
On February 24, 2026, Cytokinetics, Incorporated reported its fourth-quarter and full-year 2025 financial results, highlighting the FDA approval and launch of MYQORZO for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the U.S., China, and Europe. The company also provided its 2026 financial guidance. MYQORZO received approvals in December 2025 and was launched in the U.S. in January 2026, with a European launch planned for Q2 2026. Cytokinetics expects to share topline results from the ACACIA-HCM trial in Q2 2026 and provided 2026 financial guidance with an expected GAAP combined R&D and SG&A expense of $830 million to $870 million.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement